Journal article

Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers

Oliver Klein, Damien Kee, Ben Markman, Michael Michael, Craig Underhill, Matteo S Carlino, Louise Jackett, Caroline Lum, Clare Scott, Adnan Nagrial, Andreas Behren, Jane Y So, Jodie Palmer, Jonathan Cebon

CLINICAL CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2020

Abstract

PURPOSE: Combination immunotherapy with anti-CTLA-4 and anti-PD-1 blockade has demonstrated significant clinical activity across several tumor types. Neuroendocrine tumors (NET) are a heterogeneous group of rare tumors with limited treatment options. CA209-538 is a clinical trial of combination immunotherapy with ipilimumab and nivolumab in rare cancers, including advanced NETs. PATIENTS AND METHODS: CA209-538 is a prospective multicenter clinical trial in patients with advanced rare cancers. Patients received treatment with nivolumab at a dose of 3 mg/kg and ipilimumab at 1 mg/kg every three weeks for four doses, followed by nivolumab 3 mg/kg every two weeks and continued for up to 96 weeks..

View full abstract

Grants

Funding Acknowledgements

The study received funding and drug support from Bristol-Myers Squibb; funding support was also provided in part by a grant from the Commonwealth of Australia, Department of Health Accelerated Research Program. A. Behren is supported by a fellowship from the Department of Health and Human Services acting through the Victorian Cancer Agency.